User:Mr. Ibrahem/Alteplase

Alteplase (t-PA) is a thrombolytic medication, used to treat acute ST elevation myocardial infarction (a type of heart attacks), pulmonary embolism associated with low blood pressure, acute ischemic stroke, and blocked central venous access devices (CVAD). It is given by injection into a vein or artery.

Common side effects are bleeding including intracranial bleeding and GI bleeding. Other side effects may rarely include allergic reactions. It is not recommended in those allergic to gentamicin. Safety of use in pregnancy is unclear. Alteplase is a manufactured form of tissue plasminogen activator. It works by converting plasminogen to plasmin in a blood clot.

Alteplase was approved for medical use in the United States in 1987. It is on the World Health Organization's List of Essential Medicines. In the United Kingdom it costs about £864 per treatment as of 2018. In the United States this amount costs about US$9,197 as of 2019.